BACKGROUND: Human papillomavirus type 16 (HPV16) seropositivity and alcohol and tobacco use have been associated with risk of head and neck squamous cell carcinoma (HNSCC). However, it is less clear whether HPV16 influences HNSCC risk associated with alcohol and tobacco use. METHODS: Incident cases of HNSCC diagnosed between December 1999 and December 2003 were identified from nine medical facilities in Greater Boston, MA. Control subjects were frequency matched to case subjects on age, sex, and town of residence. A total of 485 case subjects and 549 control subjects reported information on lifetime smoking and alcohol consumption and provided sera, which was used to determine presence of HPV16 antibodies. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of HNSCC risk by alcohol consumption (drinks per week: < 3, 3 to < 8, 8 to < 25, > or = 25) and smoking (pack-years: none, > 0 to < 20, 20 to < 45, > or = 45), adjusting for age, sex, race, education, and HPV16 serology. Polytomous logistic regression was used to estimate odds ratios and 95% confidence intervals for the association of HPV16 serology, alcohol consumption, and tobacco use in site-specific analyses. All statistical tests were two-sided. RESULTS: The strongest risk factors by tumor site were smoking for laryngeal cancer, alcohol for cancer of the oral cavity, and HPV16 for pharyngeal cancer. For pharyngeal cancer, risk increased with increasing alcohol consumption (OR(> or = 25 versus < 3 drinks per week) = 5.1, 95% CI = 2.4 to 11.0) and smoking (OR(> or = 45 pack-years versus never smoker) = 6.9, 95% CI = 3.1 to 15.1) among HPV16-seronegative subjects but not among HPV16-seropositive subjects (P(interaction, HPV16 serology and alcohol) = .002; P(interaction, HPV16 serology and smoking) = .007). Among light drinkers or never smokers, HPV16 seropositivity was associated with a 30-fold increased risk of pharyngeal cancer. CONCLUSIONS: Alcohol or tobacco use does not further increase risk of HPV16-associated pharyngeal cancer. HNSCC risk associated with smoking, alcohol, and HPV16 differs by tumor site.
BACKGROUND:Human papillomavirus type 16 (HPV16) seropositivity and alcohol and tobacco use have been associated with risk of head and neck squamous cell carcinoma (HNSCC). However, it is less clear whether HPV16 influences HNSCC risk associated with alcohol and tobacco use. METHODS: Incident cases of HNSCC diagnosed between December 1999 and December 2003 were identified from nine medical facilities in Greater Boston, MA. Control subjects were frequency matched to case subjects on age, sex, and town of residence. A total of 485 case subjects and 549 control subjects reported information on lifetime smoking and alcohol consumption and provided sera, which was used to determine presence of HPV16 antibodies. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of HNSCC risk by alcohol consumption (drinks per week: < 3, 3 to < 8, 8 to < 25, > or = 25) and smoking (pack-years: none, > 0 to < 20, 20 to < 45, > or = 45), adjusting for age, sex, race, education, and HPV16 serology. Polytomous logistic regression was used to estimate odds ratios and 95% confidence intervals for the association of HPV16 serology, alcohol consumption, and tobacco use in site-specific analyses. All statistical tests were two-sided. RESULTS: The strongest risk factors by tumor site were smoking for laryngeal cancer, alcohol for cancer of the oral cavity, and HPV16 for pharyngeal cancer. For pharyngeal cancer, risk increased with increasing alcohol consumption (OR(> or = 25 versus < 3 drinks per week) = 5.1, 95% CI = 2.4 to 11.0) and smoking (OR(> or = 45 pack-years versus never smoker) = 6.9, 95% CI = 3.1 to 15.1) among HPV16-seronegative subjects but not among HPV16-seropositive subjects (P(interaction, HPV16 serology and alcohol) = .002; P(interaction, HPV16 serology and smoking) = .007). Among light drinkers or never smokers, HPV16 seropositivity was associated with a 30-fold increased risk of pharyngeal cancer. CONCLUSIONS:Alcohol or tobacco use does not further increase risk of HPV16-associated pharyngeal cancer. HNSCC risk associated with smoking, alcohol, and HPV16 differs by tumor site.
Authors: Xinmiao Tan; Heather H Nelson; Scott M Langevin; Michael McClean; Carmen J Marsit; Tim Waterboer; Michael Pawlita; Karl T Kelsey; Dominique S Michaud Journal: Cancer Causes Control Date: 2014-11-15 Impact factor: 2.506
Authors: Alice L Tang; Samantha J Hauff; John H Owen; Martin P Graham; Michael J Czerwinski; Jung Je Park; Heather Walline; Silvana Papagerakis; Jay Stoerker; Jonathan B McHugh; Douglas B Chepeha; Carol R Bradford; Thomas E Carey; Mark E Prince Journal: Head Neck Date: 2011-12-13 Impact factor: 3.147
Authors: Anil K Chaturvedi; Barry I Graubard; Tatevik Broutian; Robert K L Pickard; Zhen-Yue Tong; Weihong Xiao; Lisa Kahle; Maura L Gillison Journal: Cancer Res Date: 2015-04-14 Impact factor: 12.701
Authors: Maura L Gillison; Tatevik Broutian; Robert K L Pickard; Zhen-you Tong; Weihong Xiao; Lisa Kahle; Barry I Graubard; Anil K Chaturvedi Journal: JAMA Date: 2012-01-26 Impact factor: 56.272
Authors: C S Furniss; M D McClean; J F Smith; J Bryan; K M Applebaum; H H Nelson; M R Posner; K T Kelsey Journal: Ann Oncol Date: 2008-12-15 Impact factor: 32.976
Authors: Katie M Applebaum; Michael D McClean; Heather H Nelson; Carmen J Marsit; Brock C Christensen; Karl T Kelsey Journal: Int J Cancer Date: 2009-06-01 Impact factor: 7.396
Authors: Silvana Papagerakis; Giuseppe Pannone; Li Zheng; Imad About; Nawar Taqi; Nghia P T Nguyen; Margarite Matossian; Blake McAlpin; Angela Santoro; Jonathan McHugh; Mark E Prince; Petros Papagerakis Journal: Exp Cell Res Date: 2014-05-05 Impact factor: 3.905
Authors: Devasena Anantharaman; David C Muller; Pagona Lagiou; Wolfgang Ahrens; Ivana Holcátová; Franco Merletti; Kristina Kjærheim; Jerry Polesel; Lorenzo Simonato; Cristina Canova; Xavier Castellsague; Tatiana V Macfarlane; Ariana Znaor; Peter Thomson; Max Robinson; David I Conway; Claire M Healy; Anne Tjønneland; Ulla Westin; Johanna Ekström; Jenny Chang-Claude; Rudolf Kaaks; Kim Overvad; Dagmar Drogan; Göran Hallmans; Göran Laurell; H B Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Nerea Larrañaga; Ruth C Travis; Domenico Palli; Aurelio Barricarte; Antonia Trichopoulou; Saitakis George; Dimitrios Trichopoulos; J Ramón Quirós; Sara Grioni; Carlotta Sacerdote; Carmen Navarro; María-José Sánchez; Rosario Tumino; Gianluca Severi; Marie-Christine Boutron-Ruault; Francoise Clavel-Chapelon; Salvatore Panico; Elisabete Weiderpass; Eiliv Lund; Inger T Gram; Elio Riboli; Michael Pawlita; Tim Waterboer; Aimée R Kreimer; Mattias Johansson; Paul Brennan Journal: Int J Epidemiol Date: 2016-05-19 Impact factor: 7.196